Resources

The Lewin Group Center for Comparative Effectiveness Research combines consulting, research, and data assets to advance the health care industry's understanding—and application—of the most effective clinical protocols available.

We invite you to review the downloadable resources in our archives to examine our work in greater detail:

CER UPDATES

• September 18, 2009 - Final report on the "Economic Analysis of Availability of Follow-on Protein Products" published online.
• June 30, 2009 - Federal Coordinating Council on CER releases Annual Report to Congress
• June 30, 2009 - Institute of Medicine releases Initial National Priorities for Comparative Effectiveness Research

LEARN MORE ABOUT OUR CER RELATED WORK

• October 2010: Health Affairs article "Special Challenges In Comparative Effectiveness Research On Children's And Adolescents' Health" published detailing how CER needs to be targeted, designed, conducted, and reported in ways that are responsive to the unique circumstances of children and adolescents
• July 2010: Lewin Group Center for CER to Develop Inventory for ASPE The Lewin Group Center for Comparative Effectiveness Research (CER) was recently selected by the Office of the Assistant Secretary for Planning and Evaluation of the Department of Health and Human Services to develop a comprehensive inventory of CER projects and assets.
• June 2010: The Lewin Group Center for CER First Annual Symposium "Responding to the National CER Agenda: Evolving Data Sources and Analytics"
• February 2010: Using Electronic Health Data to Support Effectiveness Research and Medical Product Safety A presentation at the Health IT Summit for Government Leaders conference on use of EHR to support CER and Medical Product Safety programs.
• January 2010: Laboratory Medicine and Comparative Effectiveness Research This report explains the rationale for CER, what CER is, and its significance for laboratory medicine. It describes the types of evidence generated by CER and how it compares with the evidence usually generated for regulatory purposes. The report summarizes current federal activities in CER that are relevant to laboratory medicine. Further, it describes implications of CER for the laboratory testing sector.
• October 28, 2009 - Presented report titled "Comparative Effectiveness Research and Personalized Medicine: From Contradiction to Synergy" at the conference on Comparative Effectiveness Research and Personalized Medicine: Science, Policy and Business hosted by the National Pharmaceutical Council and the Personalized Medicine Coalition.
• Other Lewin publications in health technology assessment and evidence-based medicine
• Lewin presentation to ISPOR 2009 on CER - The CER Train Has Left ... for Where? Are You on Board?
• i3 presentation on The Merits of Observational Research
• i3 webinar on CER - Comparative Effectiveness Requirements and the Payer - Recorded September 16, 2008
• OptumInsight Life Sciences CER and Late Phase Consulting   

Full reference and link to abstract	PubMed Reference
Harley CR, Gandhi S, Heien H, Nelson SP. The comparative effectiveness of rosuvastatin vs. other statins in patients with an increased risk of failure to reach NCEP ATP III goal. Int J Clin Pract. 2008;62(6):889-95.	PM:18479282
Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008;9(5):669-76.	PM:18345946
Stanford RH, Fuhlbrigge A, Riedel A, Rey GG, Stempel D. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr.Med.Res.Opin. 2008:24(11):3141-8.	PM:18838055
Xin Y, Sikirica V, Schein J, Grant R, Zarotsky V, Doshi D, Benson C, Riedel A. Treatment Failure Rates and Health Care Utilization and Costs Among Patients with Community-Acquired Pneumonia Treated with Levofloxacin or Macrolides in an Outpatient Setting: A Retrospective Claims Database Analysis. Clin Ther, 2008;30(2): 358-371.	PM:18343274
Kobelt G, Berg J. Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the Cost-Effectiveness of a New Treatment for MS (natalizumab) compared to Current Standard Practice in Sweden. Multiple Sclerosis 2008;14(5):679-90.	PM:18566030
Lindgren P, Buxton M, Kahan T, Poulter N, Dahlöf B, Sever S, Wedel H, Jönsson B. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlopidine based treatment is cost-effective compared to an atenolol-based regimen. ASCOT Trial Investigators. Heart 2008;94(2):e4.	PM:17916665
Aballea S, Cure S, Vogelmeier C, Wiren A. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta (2)-agonists for asthma maintenance treatment in Germany. Int J Clin Pract. 2008;62(12):1870-9.	PM:18803555
Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lieu PL, Finnern HW. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless leg syndrome. Sleep Med. 2008;9(7):715-26.	PM:18226947
Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Kim Le T, Garcia-Cebrian A, Monz B. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology 2009;9:6.	PM:19208243